Monitoring unfractionated heparin (UFH) therapy: Which anti factor Xa assay is appropriate?
Vera Ignjatovic, Robyn Summerhayes, Andrew Gan, Jenny Than, Anthony Chan, Andrew Cochrane, Martin Bennett, Stephen Horton, Frank Shann, Geoff Lane, Maree Ross-Smith, Paul Monagle
THROMBOSIS RESEARCH | PERGAMON-ELSEVIER SCIENCE LTD | Published : 2007
INTRODUCTION: Anti-Factor Xa (Anti-Xa) assays specifically determine the anticoagulant activity of UFH by measuring the ability of heparin-bound Antithrombin (AT) to inhibit a single enzyme, Factor Xa (FXa). Recent improvements in the automation, cost-effectiveness and accessibility of the assay to clinicians, have resulted in the Anti-Xa assay becoming a part of daily clinical practice in many institutions. OBJECTIVES: We hypothesized that different Anti-Xa assays have different applicability for use in clinical settings, depending on the amount of UFH administered. This was investigated in a tertiary paediatric institution. MATERIALS AND METHODS: Samples were collected from children receiv..View full abstract